AR and Beyond: ctDNA Maps Resistance Evolution in mCRPC
Longitudinal plasma cfDNA profiling from the phase 3 Alliance A031201 trial revealed divergent resistance trajectories in mCRPC. Rapid progressors harbored non-AR alterations suggesting intrinsic resistance, whereas delayed progressors showed progressive AR amplifications, structural rearrangements and extrachromosomal DNA-associated evolution. These findings support biomarker-guided strategies targeting AR-dependent and AR-independent disease states.
Authors
- Christopher A. Maher (ORCID: https://orcid.org/0000-0002-9035-603X)
- Prof. Pradeep S. Chauhan
- Aadel A. Chaudhuri (ORCID: https://orcid.org/0000-0003-3115-3061)
- Russell K. Pachynski (ORCID: https://orcid.org/0000-0002-8966-7631)
Institutions
- Mayo Clinic (US)
- Washington University in St. Louis (US)
- Cancer Clinic (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
- Alvin J. Siteman Cancer Center (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-04-17
- DOI
- https://doi.org/10.1158/1078-0432.ccr-26-0478
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Foundation Medicine
- National Cancer Institute